EAN 2020

European Academy of Neurology

Long-term safety of ND0612 in idiopathic Parkinson’s disease

Novel genetic association with resistance to ERC tau deposition

Sustained seizure reductions with cannabidiol for Lennox-Gastaut Syndrome

MRI-based clustering of MS patients

Reassuring real-world safety profile of 3 CGRP inhibitors

Switching from natalizumab to moderate- versus high-efficacy DMT in MS

Neurological manifestations of COVID-19 in Europe

Long-term cardiovascular safety of erenumab in migraine patients

High NEDA rates after 2 years of ocrelizumab

Extubation after thrombectomy: the sooner, the better

Serum NfL predicts long-term clinical outcomes in MS

Statins to prevent stroke: benefits “greatly exceed” risks

White matter matters in Parkinson’s disease

How genetic testing can contribute to epilepsy management

Pegzilarginase highly effective in arginase-1 deficiency

Allogeneic Epstein-Barr virus-targeted T-cell immunotherapy for progressive MS

Diastolic dysfunction novel risk factor for cognitive impairment

Superior efficacy ponesimod vs teriflunomide in OPTIMUM study

Top image: @ iStockPhoto: koto_feja

The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.